MaaT Pharma SA

Paris Stock Exchange MAAT.PA

MaaT Pharma SA EBIT for the year ending December 31, 2023: USD -22.75 M

MaaT Pharma SA EBIT is USD -22.75 M for the year ending December 31, 2023, a -54.70% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

MaaT Pharma SA EBIT for the year ending December 31, 2022 was USD -14.71 M, a -42.90% change year over year.
MaaT Pharma SA EBIT for the year ending December 31, 2021 was USD -10.29 M, a -24.86% change year over year.
MaaT Pharma SA EBIT for the year ending December 31, 2020 was USD -8.24 M, a -7.07% change year over year.
MaaT Pharma SA EBIT for the year ending December 31, 2019 was USD -7.70 M, a -30.06% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

Paris Stock Exchange: MAAT.PA

MaaT Pharma SA

CEO	Mr. Herve Affagard
IPO Date	Nov. 8, 2021
Location	France
Headquarters	70 Avenue Tony Garnier
Employees	54
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials

Description

MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.

Key trends

Past 5 years